News and Updates

Greetings from Barcelona, Spain! From March 11–14, 2026, the world’s leading type 1 diabetes (T1D) researchers, healthcare professionals, and industry partners gathered to share groundbreaking advances in T1D science—and Breakthrough T1D–supported work (and staff) were front and center. Below is everything you need to know from the first two days of this remarkable conference, including […]

Tzield is the first approved disease-modifying therapy for type 1 diabetes, but Breakthrough T1D will make sure it’s not the last.

One of our most promising avenues toward cures for type 1 diabetes (T1D) is cell therapies. Cell therapies replace destroyed beta cells with functional, insulin-producing cells to restore insulin therapy independence. Right now, there are nearly a dozen cell therapies in clinical testing—and OPF-310 is one of them. OPF-310 cells are derived from porcine (pig) […]

This article was written by Alecia Wesner (pictured above, right), a Participant Advisory Council (PAC) member, a Clinical Trial Education Volunteer, and long-time Breakthrough T1D supporter. Alecia’s story details her lived experiences with type 1 diabetes, participation in clinical trials, and her journey to joining the PAC. The views expressed by the author are her […]

What’s happening? Continuous ketone monitoring (CKM) is on its way. A new paper in The Lancet Diabetes & Endocrinology, titled “International expert recommendations on the application and utility of continuous ketone monitoring for people with diabetes,” was published by Breakthrough T1D and expert collaborators, spearheaded by our Chief Medical Officer, International, Thomas Danne, M.D., Ph.D. […]

How quickly a year goes by—and a lot has happened for type 1 diabetes (T1D) in 2025! In these last few weeks leading up to the new year, Breakthrough T1D would like to take a moment to reflect on how far we’ve come in the past 365 days. Read on for the greatest T1D accomplishments […]

Closing the gap between access to and adoption of type 1 diabetes therapies is a mission priority. Chris Dunn represents these efforts in action.

What is the pipeline? Every new medical device, therapy, treatment, and drug—including those for type 1 diabetes (T1D)—goes through the drug development pipeline. Getting a new therapy or device from the earliest stages of research eventually into the hands of people with T1D is a complicated process. Science takes time (from years to decades!), money […]

There are three ways we can get to cures for type 1 diabetes faster: cell therapies, early detection, and disease-modifying therapies.

What’s happening? Today, Bayer shared data from the phase 3 FINE-ONE clinical trial. These results, which were presented at the American Society of Nephrology Kidney Week in Houston, TX, showed that finerenone (Kerendia™/Firialta™) significantly reduces urine albumin-to-creatinine ratio (UACR), a measure of kidney damage, in people with chronic kidney disease (CKD) associated with type 1 […]